1/27/2025NHSA Issues Two New Documents on DRG Payment Management

1/27/2025State Council Releases Final Antitrust Guidelines for the Pharmaceutic...

1/27/2025AsiFlyer Secures Series Pre-A++ Funding to Advance Botulinum Toxin Dru...

1/27/2025GeneQuantum Announces Strategic Collaborations with Biohaven and Aimed...

1/27/2025Lumiere Secures Series Pre-A Funding to Advance Gene Editing Research

1/24/2025Recent Executive Moves

1/24/2025Snapshot of BMI System Financial Performance in 2024

1/24/2025NHSA Solicits Information on Low-Transaction Drugs in the National Dru...

1/24/2025NMPA Issues Announcement on Expanding the Implementation Scope of the...

1/24/2025Ab&B Biotech Submits IPO Application to Hong Kong Stock Exchange

1/24/2025Hengrui's Insulin Degludec BLA Accepted by China's NMPA

1/23/2025TargetRx Secures $50 Million in Series C Financing to Propel Global Cl...

1/23/2025Belief BioMed Announces IND Clearance by FDA for DMD Gene Therapy Cand...

1/23/2025CDE Issues the Technical Guidelines for Non-Clinical Research of Proph...

1/23/2025CDE Issues the Technical Guidelines for Pharmaceutical Studies of Monk...

1/23/2025CDE Issues the Guidelines for Writing Clinical-Related Information in ...

1/22/2025NHSA Issues the Notice on Establishing BMI Data Working Groups to Bett...

1/22/2025CDE Issues the Technical Guideline for the Study of Storage Period for...

1/22/2025Degron Secures $20M in Series A+ Financing to Advance Molecular Glue T...

1/22/2025Imbioray Secures Series A+ Financing to Advance NK Cell Therapy Pipeli...

1/22/2025Fosun Pharma’s Bid to Privatize Henlius Fails After Shareholder Rejec...

1/22/2025Innovent Advances PD-1/IL-2α-Bias Bispecific Antibody IBI363 into Pha...

1/22/2025YolTech to Initiate a Clinical Trial of FIC Bone Marrow-Targeted In V...

1/22/2025Shanghai Bao Pharma Files for IPO on HKSE

1/22/2025Qyuns Thera Secures CSRC Approval for Full H-share Circulation

1/21/2025China's Biopharma R&D Expands Global Influence in 2024

1/21/2025China's BMI Fund Reports Balanced Budget and Surplus for 2024

1/21/2025ArriVent Enters Exclusive License with Lepu Biopharma for MRG007, an A...

1/21/2025Sichuan Biokin Refiles for Hong Kong IPO Following Lapsed Application

1/21/2025 China-based Ascentage Pharma Targets $149M in US IPO

Page:45/59 Total number of articles:1741: [First][<<] [43] [44] [45] [46] [47] [>>] [End]